Follow
carlo albera
carlo albera
Professore Associato di Malattie dell'Apparato Respiratorio
Verified email at unito.it
Title
Cited by
Cited by
Year
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
PW Noble, C Albera, WZ Bradford, U Costabel, MK Glassberg, ...
The Lancet 377 (9779), 1760-1769, 2011
19252011
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
RP Baughman, M Drent, M Kavuru, MA Judson, U Costabel, R du Bois, ...
American journal of respiratory and critical care medicine 174 (7), 795-802, 2006
7002006
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
TE King Jr, C Albera, WZ Bradford, U Costabel, P Hormel, L Lancaster, ...
The Lancet 374 (9685), 222-228, 2009
5872009
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference
RM Du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ...
American journal of respiratory and critical care medicine 184 (12), 1382-1389, 2011
4532011
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
RM du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ...
4412011
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
RM du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ...
American journal of respiratory and critical care medicine 184 (4), 459-466, 2011
4282011
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
PW Noble, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ...
European Respiratory Journal 47 (1), 243-253, 2016
3692016
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
SD Nathan, C Albera, WZ Bradford, U Costabel, I Glaspole, MK Glassberg, ...
The Lancet Respiratory Medicine 5 (1), 33-41, 2017
2512017
An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial
D Khanna, C Albera, A Fischer, N Khalidi, G Raghu, L Chung, D Chen, ...
The Journal of rheumatology 43 (9), 1672-1679, 2016
2142016
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
RM du Bois, C Albera, WZ Bradford, U Costabel, JA Leff, PW Noble, ...
European Respiratory Journal 43 (5), 1421-1429, 2014
1762014
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
MA Judson, RP Baughman, U Costabel, M Drent, KF Gibson, G Raghu, ...
European Respiratory Journal 44 (5), 1296-1307, 2014
1722014
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with …
SD Nathan, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ...
Thorax 71 (5), 429-435, 2016
1612016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
C Albera, U Costabel, EA Fagan, MK Glassberg, E Gorina, L Lancaster, ...
European Respiratory Journal 48 (3), 843-851, 2016
1462016
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials
TE King Jr, C Albera, WZ Bradford, U Costabel, RM du Bois, JA Leff, ...
American journal of respiratory and critical care medicine 189 (7), 825-831, 2014
1332014
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
LH Lancaster, JA de Andrade, JD Zibrak, ML Padilla, C Albera, ...
European respiratory review 26 (146), 2017
1242017
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
L Richeldi, ERF Pérez, U Costabel, C Albera, DJ Lederer, KR Flaherty, ...
The Lancet Respiratory Medicine 8 (1), 25-33, 2020
1222020
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
J Behr, E Bendstrup, B Crestani, A Günther, H Olschewski, CM Sköld, ...
The Lancet Respiratory Medicine 4 (6), 445-453, 2016
1172016
An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)
U Costabel, C Albera, LH Lancaster, CY Lin, P Hormel, HN Hulter, ...
Respiration 94 (5), 408-415, 2017
1132017
Comprehensive assessment of the long‐term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
D Valeyre, C Albera, WZ Bradford, U Costabel, TE King Jr, JA Leff, ...
Respirology 19 (5), 740-747, 2014
1122014
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
L Lancaster, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ...
BMJ open respiratory research 3 (1), e000105, 2016
1112016
The system can't perform the operation now. Try again later.
Articles 1–20